Physician profile
Sonia Mehta
NPI 1902004401
$48,909.33
in general payments reported to CMS, 2019-2025
9 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $2,855 · 2021: $660 · 2022: $686 · 2023: $1,503 · 2024: $14K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $11K · Food and Beverage: $1,097 · Travel and Lodging: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,050.00 |
| Consulting Fee | $10,870.00 |
| Food and Beverage | $1,096.93 |
| Travel and Lodging | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35,443.05 | 2023-2025 | Izervay |
| Genentech USA, INC. | $6,076.01 | 2020-2024 | Vabysmo |
| Merck Sharp & Dohme LLC | $5,390.00 | 2019-2025 | |
| Abbvie INC. | $1,621.68 | 2023-2025 | |
| Astellas Pharma Global Development | $148.66 | 2025 | Izervay |
| Alcon Vision LLC | $130.47 | 2023 | Clareon |
| Apellis Pharmaceuticals, INC. | $73.86 | 2023 | Syfovre |
| Novo Nordisk INC | $25.60 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.